Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Just 20 years ago, 80% to 90% of people with wet AMD developed vision loss that met the definition of legal blindness. But in 2005, the first in a new class of drugs called anti-VEGF agents was ...

Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases like wet age-related macular degeneration (AMD) with a new approval for Eylea 8mg.

Yesafili is a VEGF inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment ...

Eylea, Regeneron’s treatment for various eye diseases, has been a key revenue driver for the company. However, the franchise has faced significant challenges in recent quarters: ...

The potential approval of AVT06, a biosimilar to Eylea®, addresses significant medical needs for patients with various eye disorders, highlighting Alvotech's commitment to patient access to vital ...

SWOT Analysis Strengths Strong R&D capabilities and track record of innovation Diverse pipeline with multiple late-stage candidates Solid financial position with significant cash reserves Successful ...

Novartis is to file its next-generation eye drug in 2018 after it won out in a head-to-head trial with Bayer/Regeneron’s rival, Eylea. Brolucizumab (RTH258) could offer a convenience advantage ...